Holen Sie sich die Stockscreener-App
68.45
0.41%
0.28
Incyte Corp Aktie (INCY) Neueste Nachrichten
Incyte (INCY) Secures FDA Approval for Monjuvi in Follicular Lym - GuruFocus
Incyte wins FDA label expansion for lymphoma drug Monjuvi (INCY) - Seeking Alpha
FDA Approves Incyte's Monjuvi for Follicular Lymphoma Treatment | INCY Stock News - GuruFocus
FDA approves Monjuvi combination therapy for follicular lymphoma By Investing.com - Investing.com Canada
FDA Approves Incyte's (INCY) Tafasitamab-Cxix for Follicular Lym - GuruFocus
Incyte Announces FDA Approval of Monjuvi® (tafasitamab-cxix) in - GuruFocus
Incyte And Two Other Stocks That May Be Priced Below Their Estimated Value - Yahoo Finance
Incyte Stock Rises on QIAGEN Deal to Advance Blood Cancer Diagnostics - Yahoo Finance
Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch
Stifel Upgrades Incyte (INCY) Rating and Raises Price Target | I - GuruFocus
Incyte (INCY) Surges on Promising Blood Disorder Treatment Results - GuruFocus
Alopecia Areata Market Expected to Experience Major Growth - openPR.com
QGEN Stock Rises in After Market Following Partnership With Incyte - Yahoo Finance
Incyte stock rating reiterated by Oppenheimer on promising cancer drug data - Investing.com Canada
Jefferies raises Incyte stock price target on promising drug data By Investing.com - Investing.com Canada
Incyte's Experimental Therapy Shows Platelet Normalization And Safety In Rare Blood Cancer Trials Across Doses - Benzinga
Qiagen and Incyte to develop diagnostic panel for myeloproliferative neoplasms - Yahoo Finance
Why Incyte Shares Are Trading Higher By Around 10%; Here Are 20 Stocks Moving Premarket - Benzinga
Jefferies raises Incyte stock price target on promising drug data - Investing.com
Incyte (INCY) Receives Upgrade Amid Promising Drug Data | INCY Stock News - GuruFocus
Incyte stock rating upgraded by Stifel on promising blood disorder drug - Investing.com
Positive Late-Breaking Data for Incyte’s First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA2025 - BioSpace
Incyte (INCY) Reports Promising Results for Novel Antibody in My - GuruFocus
Incyte (INCY) Receives Upgrade to Buy with $107 Price Target | INCY Stock News - GuruFocus
Incyte (INCY) Reports Promising Results for Novel Antibody in Myeloproliferative Neoplasms | INCY Stock News - GuruFocus
QIAGEN And Incyte Partner To Create New Test For Rare Blood Cancers - Nasdaq
Incyte (INCY) Targets $1B Growth by 2029 with New Drug Launches - Insider Monkey
QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs) - Quantisnow
Positive Late-Breaking Data for Incyte's First-in-Class mutCALR- - GuruFocus
Incyte Announces FDA Approval of Monjuvi® (tafasitamab-cxix) in Combination with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma – Company AnnouncementFT.com - Financial Times
Incyte’s SWOT analysis: stock faces patent cliff as pipeline progress mixed - Investing.com
Specialised Therapeutics announces expanded partnership with Incyte - Yahoo Finance
Specialised Therapeutics Expands Partnership with Incyte to Incl - GuruFocus
Phase 3 Data for Incyte’s Retifanlimab (Zynyz®) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet - BioSpace
Incyte (INCY) Reports Promising Results from Phase 3 Retifanlimab Trial | INCY Stock News - GuruFocus
Phase 3 Data for Incyte's Retifanlimab (Zynyz®) in Patients with - GuruFocus
) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet - Business Wire
Specialised Therapeutics expands oncology portfolio with Incyte deal - Investing.com
Incyte (INCY) Expands Partnership with Specialised Therapeutics in Asia-Pacific | INCY Stock News - GuruFocus
Incyte Doubles Down in Asia-Pacific: New Partnership Brings Breakthrough Cancer Treatments to High-Need Markets - Stock Titan
Incyte Corporation (INCY) Announces Amendments to Stock Incentiv - GuruFocus
Incyte stockholders endorse plan amendments and board members By Investing.com - Investing.com Canada
Incyte stockholders endorse plan amendments and board members - Investing.com
Incyte stock holds steady as UBS maintains neutral rating - Investing.com
Incyte to Showcase Groundbreaking Hematology/Oncology Data at EHA 2025 - MSN
Incyte at Goldman Sachs Conference: Growth Beyond Jakafi - Investing.com
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | INCY Stock News - GuruFocus
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo
Alnylam, Incyte and GSK led biopharma gains amid earnings volatility - BioWorld MedTech
Morgan Stanley Maintains Hold Rating on Incyte (INCY) Stock - Insider Monkey
Stifel maintains hold rating on Incyte stock, keeps $75 price target - Investing.com
TD Cowen maintains Buy rating on Incyte stock, sees promising data - Investing.com
TD Cowen Reiterates Buy Rating on Incyte (INCY) - StreetInsider
JPMorgan maintains neutral rating on Incyte stock amid trial data - Investing.com
JPMorgan Reiterates Neutral Rating on Incyte (INCY) - StreetInsider
Where Incyte Stands With Analysts - Benzinga
Citi maintains buy rating for Incyte stock amid promising trial data - Investing.com
Incyte (INCY) Rises on Positive Data for Thrombocythemia Treatme - GuruFocus
Incyte (INCY) Unveils Positive Data on mCALR Inhibitor for Rare Blood Disorder | INCY Stock News - GuruFocus
BMO Capital reiterates underperform rating on Incyte stock - Investing.com
Citi Reiterates Buy Rating on Incyte (INCY) - StreetInsider
Incyte (INCY) Maintains Neutral Rating with UBS Target at $61 | - GuruFocus
UBS Expresses Caution on Incyte (INCY) Due to Safety Concerns | - GuruFocus
Incyte's (INCY) mCALR Shows Promise in Essential Thrombocythemia - GuruFocus
Incyte's (INCY) mCALR Shows Promise in Essential Thrombocythemia | INCY Stock News - GuruFocus
Incyte reveals promising trial data for essential thrombocythemia treatment - Investing.com
Incyte stock rises following EHA presentation acceptance By Investing.com - Investing.com Nigeria
0.68%
0.50%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):